Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 122, Issue 10, Pages 1535-1543
Publisher
Springer Science and Business Media LLC
Online
2020-03-25
DOI
10.1038/s41416-020-0811-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
- (2019) Qiuhua Luo et al. CANCER LETTERS
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint blockade therapy for esophageal squamous cell carcinoma
- (2018) Kazuto Harada et al. Journal of Thoracic Disease
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
- (2018) Hong Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety
- (2017) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
- (2017) Chan-Young Ock et al. Oncotarget
- Oesophageal cancer
- (2017) Elizabeth C. Smyth et al. Nature Reviews Disease Primers
- PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
- (2017) Taisuke Yagi et al. ANNALS OF SURGERY
- Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy
- (2016) Koji Tanaka et al. CANCER SCIENCE
- New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints
- (2016) V. E. Wang et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
- (2016) Yusuke Inoue et al. Oncotarget
- Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
- (2016) Anja Derer et al. Frontiers in Immunology
- 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
- (2016) Lauren Van Der Kraak et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
- (2015) Jaemoon Koh et al. MODERN PATHOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells
- (2015) CHANGSEN LENG et al. ONCOLOGY REPORTS
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
- (2011) W. Joost Lesterhuis et al. JOURNAL OF CLINICAL INVESTIGATION
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started